MEI Pharma Receives Orphan Status For Lead Drug Candidate Pracinostat For Treatment Of Acute Myeloid Leukemia

On February 28, 2014 MEI Pharma announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s investigational drug Pracinostat for the treatment of acute myeloid leukemia (AML) (Press release MEI Pharma, FEB 28, 2014, View Source [SID:1234500202]).